BNET Industries
GlaxoSmithKline Plc. is in the Pharma Industry
Latest News and Analysis
Sanofi Hit By Generic Plavix Threat in Europe
By Ben Hirschler LONDON (Reuters) - French drugmaker Sanofi-Aventis SASY, which briefly encountered generic competition to its second-biggest product Plavix in the United States in 2006 and 2007, now faces a similar threat in Europe. Schweizerhall SWHN, a Swiss generic drug company, said...
Takeda Sees Big Profit Slump on Millennium Costs
By Edwina Gibbs TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd posted a 77 percent drop in quarterly operating profit as it spent to boost its pipeline, and forecast a sharp fall in annual income linked to the costs of its $8...
Glaxo Bond Boosts Chances of Euro Mega Deals
By Natalie Harrison LONDON (Reuters UK) - GlaxoSmithKline's GSK well-received $9 billion (4.6 billion pound) bond this week, the largest dollar issue by a non-U.S. corporate in seven years, has raised confidence of possible euro mega deals in the next few months. The success of the...
Government Seen Risking Business Exodus Over Tax
LONDON (Reuters UK) - Some of the biggest names in British business have told the government that it risks a corporate exodus if it presses ahead with tax proposals on foreign earnings, newspapers said on Sunday. The Sunday Times and Sunday Telegraph said a delegation ...
Glaxo Wins U.S. FDA Approval For Wider Advair Use
By Susan Heavey WASHINGTON (Reuters UK) - U.S. health regulators have said GlaxoSmithKline Plc's GSKGSK Advair is safe and effective to more widely treat patients with chronic obstructive pulmonary disease COPD, the drugmaker said on Wednesday. Glaxo's approval comes the same day as rival AstraZeneca...
Glaxo Wins FDA Approval For Wider Advair Use
WASHINGTON (Reuters) - U.S. health regulators have said GlaxoSmithKline Plc's GSKGSK Advair is safe and effective to more widely treat patients with chronic obstructive pulmonary disease COPD, the drugmaker said on Wednesday. Glaxo's approval comes the same day as rival AstraZeneca...
New Glaxo Chief Targets Emerging Markets
By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK will make emerging markets a priority for future growth by creating a new region targeting such countries, the company's incoming chief executive Andrew Witty said on Wednesday. It will also look for new business opportunities in these...
Banks and Oils Lead FTSE to Close Up
By Dominic Lau LONDON (Reuters UK) - The top share index ended up 0.7 percent on Friday as optimism that banks had seen the worst of credit-related writedowns lifted the sector and oil stocks tracked higher crude prices. The FTSE 100 closed up 40.7 points...
AstraZeneca Q1 Sales Fall Short as Nexium Tumbles
By Ben Hirschler LONDON (Reuters UK) - AstraZeneca AZN nudged up its forecast for 2008 earnings on Thursday, but sales of ulcer pill Nexium and other key drugs in the first quarter were weaker than hoped for, knocking its shares. "The sales trends of most of...
Schering Shares Jump After Profit Beats Forecasts
By Ransdell Pierson NEW YORK (Reuters) - Schering-Plough Corp SGP, whose stock has been battered this year by a failed trial of its Vytorin cholesterol drug, reported a quarterly profit well above Wall Street forecasts thanks to cost controls, lifting its...
Glaxo Profits Fall as Avandia and Generics Weigh
By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK profits fell 5 percent in the first quarter, hit by tumbling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said. The decline was less than analysts had feared, helped...
Glaxo Profit Fall as Generics Weigh
By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline Plc GSK profits fell 5 percent in the first quarter, hit by tumbling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said. The decline was less than analysts...
Glaxo to Buy Biotech Sirtris in $720 Mln Deal
By Ransdell Pierson NEW YORK (Reuters UK) - GlaxoSmithKline GSK said on Tuesday it had agreed to buy biotechnology company Sirtris Pharmaceuticals Inc SIRT for $720 million (360.69 million pounds) in cash, in hopes its medicines that modulate an aging-related family of enzymes will be...
Cost Cutting Boosts Novartis Q1 Profit
By Sam Cage ZURICH (Reuters) - First-quarter net profit at Swiss drugmaker Novartis AG NOVN rose 10 percent to $2.31 billion, helped by cost cuts and the weak dollar, easily beating forecasts and sending its shares up more than 5 percent....
Glaxo Boosts Biotech With Regulus Deal
By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK boosted its position in biotech on Thursday by signing a deal that could be worth up to $600 million (303 million pounds) with Regulus Therapeutics, taking it into the hot area of RNA technology. The tie-up covers...
Roche Sales, Stock Hit By Tamiflu Slump
By Sam Cage ZURICH (Reuters) - Roche Holding AG ROG missed forecasts with a meager 2 percent increase in first-quarter sales in local currencies, hit by plunging Tamiflu revenue and a slowing pace of growth for cancer drugs. Its stock fell 3.5 percent...
GlaxoSmithKline: GlaxoSmithKline Consumer Healthcare Helps Smokers Quit With ASP.NET, C#, Commerce Server 2002 and the .NET Framework
GlaxoSmithKline Consumer Healthcare is the over-the-counter business unit of GSK, and shares the GSK corporate mission to improve the quality of human life. It wanted to redesign and re-architect its family of smoking cessation web sites, in order to extend its ability to support smokers throughout their stages of quitting,...
Additional Resources
Business allies rally to Brown in row over tax exodus
Jean-Pierre Garnier, the chief executive of the world's fourth biggest pharmaceutical group, GlaxoSmithKline, offered respite to the beleaguered Government yesterday, saying that his company does not intend to join the exodus of those leaving the UK for lighter taxes in Ireland. Mr Garnier, an ally of Gordon...
Medicago Appoints New VP Manufacturing
Medicago Inc. (TSX VENTURE: MDG) today announced that Brigitte Barbeau has been appointed Vice President, Manufacturing, and is expected to join the company on May 26, 2008. In this newly created position, Ms. Barbeau will lead the Company's manufacturing functions to accelerate the development of Medicago's H5N1 pandemic influenza vaccine...
Targacept Reports First Quarter 2008 Financial Results
WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics[TM], today reported its financial results for the first quarter ended March 31, 2008. Targacept reported a net loss of $5.8 million for the first quarter of 2008,...
- Next »
- page 1 of 259
- « Previous
Sort byClose
GlaxoSmithKline Plc. Company Info
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
